首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1707282

尿道感染药物市场：依药物、适应症及地区划分

Urinary Tract Infection Therapeutic Market, By Drug, By Indication, and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032

出版日期: 2025年03月03日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2025 年全球尿道感染药物市场规模估计为 94 亿美元，预计到 2032 年将达到 117.1 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 3.20%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	94亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	3.20%	2032年价值预测	117.1亿美元

数字。 2025年尿道感染治疗市场占有率（按地区）

尿道感染（UTI）是泌尿器官系统任何部位的感染疾病。女性罹患尿道感染的风险高于男性。尿道感染(UTI) 通常由粪便中的细菌进入尿道所引起。尿道感染的首要治疗方法通常是抗生素。常用于治疗无併发症的尿道感染的药物包括甲氧芐啶-磺胺甲噁唑（Bactrim、Bactrim DS）、磷霉素（Monurol）、呋喃妥因（Macrodantin、Macrobid、Furadantin）、头孢氨芐和头孢曲松。

市场动态：

尿道感染盛行率高、糖尿病和肾结石盛行率上升、老年人口成长以及对新型治疗剂开发的日益关注是预测期内推动全球尿道感染药物市场成长的关键因素。

2021年10月，Spero Therapeutics Inc.向美国食品药物管理局（USFDA）提交了新药认证（NDA），寻求核准氢溴酸替比培南片用于治疗由敏感微生物引起的复杂性尿道感染（cUTI），包括肾盂肾炎。此外，2021年9月，我们推出了Viapenem，用于治疗腹腔内感染疾病、下呼吸道感染疾病和复杂性尿道感染。

2020年7月，美国食品药物管理局（FDA）核准抗生素Recarbrio（Imipenem、西司他丁、瑞利巴坦）用于治疗成人复杂性尿道感染（cUTI）及复杂性腹腔内感染疾病（cIAI）。

本研究的主要特点

本报告对全球尿道感染治疗市场进行了详细分析，并以 2024 年为基准年，展示了预测期（2025-2032 年）的市场规模和復合年增长率。
它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
该报告涵盖了全球尿道感染药物市场的主要企业概况，基于以下参数，例如公司亮点、产品系列、主要亮点、绩效和策略。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、新兴趋势、市场扩张和行销策略做出明智的决策。
全球尿道感染药物市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
可以透过用于分析全球尿道感染药物市场的各种策略矩阵来促进相关人员的决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 9.4 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	3.20%	2032 Value Projection:	USD 11.71 Bn

A urinary tract infection (UTI) is an infection in any part of the urinary system. Women are at greater risk of developing a urinary tract infection compared to men. Urinary tract infections (UTIs) are usually caused by bacteria from poo entering the urinary tract. Antibiotics usually are the first treatment for urinary tract infections. Medicines commonly used for simple UTI s include Trimethoprim and sulfamethoxazole (Bactrim, Bactrim DS), Fosfomycin (Monurol), Nitrofurantoin (Macrodantin, Macrobid, and Furadantin), Cephalexin, and Ceftriaxone.

Market Dynamics:

High prevalence of urinary tract infection, increasing prevalence of diabetes and kidney stones, increasing geriatric population, and increase in focus on the development of novel therapeutics are some major factors expected to drive growth of the global urinary tract infection therapeutic market during the forecast period.

In October 2021, Spero Therapeutics Inc. submitted a new drug application (NDA) to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible microorganisms. Moreover, in September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or complicated urinary tract infections.

In July 2020, the U.S. Food and Drug Administration (FDA) approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Key features of the study:

This report provides in-depth analysis of the global urinary tract infection therapeutic market, and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2025-2032), considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global urinary tract infection therapeutic market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global urinary tract infection therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global urinary tract infection therapeutic market.

Detailed Segmentation:

Global Urinary Tract Infection Therapeutic Market By Drug:
- Penicillin and Combinations
- Quinolones
- Cephalosporin
- Azoles and Amphotericin B
- Nitrofurans
- Other Drugs
Global Urinary Tract Infection Therapeutic Market By Indication;
- Complicated UTI
- Uncomplicated UTI
- Other Indications
Global Urinary Tract Infection Therapeutic Market By Geography:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Pfizer
- Novartis AG
- Cipla Inc.
- Bayer AG
- AstraZeneca
- Shionogi & Co. Ltd.
- GlaxoSmithKline PLC

Market Dynamics
- High prevalence of urinary tract infection across the globe
- Adverse effects associated with the use of UTI medication
- Increase in focus on the development of novel drugs
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Urinary Tract Infection Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Urinary Tract Infection Therapeutic Market, By Drug, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Penicillin and Combinations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Quinolones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Cephalosporin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Azoles and Amphotericin B
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Nitrofurans
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Other Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Urinary Tract Infection Therapeutic Market, By Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Complicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Uncomplicated UTI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Urinary Tract Infection Therapeutic Market, By Geography, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Middle East and Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
Rest of World
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)

8. Competitive Landscape

Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Shionogi & Co. Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

9. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

10. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

尿道感染药物市场：依药物、适应症及地区划分